Group 1 - The company is undergoing a critical transformation period in Q1 2025, facing sales pressure due to multiple factors including the nationwide expansion of traditional Chinese medicine procurement and retail pharmacy integration [1] - In Q2, the company plans to leverage the execution of new procurement standards to enhance terminal development coverage and manage market uncertainties effectively [1] - The company is integrating its existing channels with Sanjiu's resources to expand product coverage and optimize cooperation with distributors, aiming to build an efficient product distribution network [1] Group 2 - The company focuses on the full industry chain of Sanqi, building brand recognition around "Sanqi is 777" and enhancing its core value through a consumer service system [2] - The brand employs a dual-driven model of "medical + retail," actively promoting its products in medical institutions and enhancing academic construction based on RCT clinical research [2] - The company is open to various new product development models, including independent research, product introduction, and potential acquisitions, while also advancing international certification and market expansion for its Artemisinin series [2]